Anticoagulant and thrombolytic drugs. I. Patho-physiological and pharmacological aspects.
D000614:Aminocaproates / Q000494:pharmacology; D000925:Anticoagulants / Q000008:administration & dosage / Q000037:antagonists & inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D000933:Antifibrinolytic Agents; D001777:Blood Coagulation / Q000187:drug effects; D001792:Blood Platelets / Q000187:drug effects; D003374:Coumarins / Q000008:administration & dosage / Q000037:antagonists & inhibitors / Q000494:pharmacology; D003509:Cyclohexanecarboxylic Acids / Q000494:pharmacology; D004176:Dipyridamole / Q000494:pharmacology; D005032:Ethylestrenol / Q000494:pharmacology; D005174:Factor XII; D005176:Factor XIII; D005337:Fibrin / Q000494:pharmacology; D005340:Fibrinogen; D005341:Fibrinolysin / Q000494:pharmacology; D005343:Fibrinolytic Agents / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use*; D006493:Heparin / Q000008:administration & dosage / Q000494:pharmacology; D006494:Heparin Antagonists; D006801:Humans; D007192:Indenes / Q000494:pharmacology; D010447:Peptide Hydrolases / Q000009:adverse effects; D010455:Peptides / Q000494:pharmacology; D010629:Phenformin / Q000494:pharmacology; D010958:Plasminogen / Q000494:pharmacology; D011479:Protamines / Q000494:pharmacology; D013300:Streptokinase / Q000494:pharmacology; D013917:Thrombin; D013923:Thromboembolism / Q000188:drug therapy* / Q000209:etiology; D014812:Vitamin K / Q000494:pharmacology
D000614:Aminocaproates; D000925:Anticoagulants; D000933:Antifibrinolytic Agents; D003374:Coumarins; D003509:Cyclohexanecarboxylic Acids; D005343:Fibrinolytic Agents; D006494:Heparin Antagonists; D007192:Indenes; D010455:Peptides; D011479:Protamines; D014812:Vitamin K; D004176:Dipyridamole; D005174:Factor XII; D005337:Fibrin; D005340:Fibrinogen; D010958:Plasminogen; D006493:Heparin; D005176:Factor XIII; D005032:Ethylestrenol; D010629:Phenformin; D010447:Peptide Hydrolases; D013300:Streptokinase; D013917:Thrombin; D005341:Fibrinolysin